SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the implications of the company's recent Phase III trial failure for its Alzheimer's drug, with some investors expressing disappointment while others see it as an opportunity to buy. Despite the setback, there is optimism surrounding Novo Nordisk's position in the weight loss market, particularly with the potential upcoming approval of its oral Wegovy pill and comparison of CagriSema vs Zepbound study results.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid mixed sentiment, as discussions range from its ties to controversial figures to its evolving stance on cryptocurrency and potential competition with Bitcoin. The community is actively debating JPMorgan's investment strategies, alleged market manipulation, and the implications of its exploration of blockchain technology and stablecoins. Additionally, some traders are monitoring technical indicators to predict JPM's short-term price movements, while others are discussing potential investigations and regulatory scrutiny.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is trending due to news of expanded robotaxi operations and partnerships, including a recent permit in Shanghai. The community is weighing the company's growth prospects against its financial performance, especially regarding profitability targets. Broader discussions involve comparing Pony AI to competitors in the autonomous driving space and assessing the impact of these developments on its market position.

Monad

Monad is trending as users discuss its upcoming launch and token distribution, particularly excitement around receiving tokens from the Coinbase presale. The community is actively speculating on potential price movements and strategies, with some comparing it to other recent launches. There's also discussion around the mainnet launch date.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to strong Q3 2025 earnings, highlighted by a 144.3% YoY revenue increase and significant growth in robotaxi revenue, with community members noting global expansion and regulatory milestones in the UAE and Switzerland. Investors are focused on WeRide's progress toward deploying hundreds of thousands of robotaxis by 2030 and its partnerships with companies like Bosch, Uber, and Grab. The conversation also includes comparisons to competitor Pony.ai, whose stock performance and institutional ownership are being weighed against WeRide's recent gains and expansion efforts.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to a newly announced MOU to acquire The Remedy Project, expanding Diginex's human-rights capabilities. Community members are actively discussing the potential for another price spike, while also considering possible pullbacks and optimal loading points. Some traders are also weighing hedging strategies amidst the volatility.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending amid uncertainty surrounding the Affordable Care Act (ACA) subsidies, with discussions focusing on potential impacts from Trump's healthcare proposals. The community is weighing the company's prospects with or without the subsidies, while some highlight Oscar Health's cash position and potential for growth in individual health plans. Options traders are active, with both bullish call buying and bearish put buying strategies being discussed.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending following the announcement of European approval for AVT03, a biosimilar to Prolia and Xgeva, used in bone disease treatment, sparking bullish sentiment. Despite some community concerns about cash flow and previous manufacturing setbacks, the biosimilar's approval and analyst upgrades are fueling optimism. Discussions center on the company's potential in the biosimilar market and strategic partnerships.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is gaining attention, with community members highlighting recent updates and increased market interest. The community emphasizes the project's potential, strong fundamentals, transparent communication, and clear utility development, with some anticipating significant growth. Discussions also touch on the token's low market cap, growing holder base, and potential for a breakout, particularly within the Solana ecosystem.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi-Aventis ($SNY) is trending amid speculation surrounding potential acquisitions, particularly in the MASH and obesity spaces, with $ALT, $GUTS, and $IVA being mentioned as possible targets. Community discussions revolve around the company's pipeline expansion needs and potential partnerships, with some users highlighting data integrity concerns around one of the speculated targets. The broader context involves Sanofi's strategic moves to strengthen its immunology and vaccine portfolio.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nvidia Corp. ($NVDA) shares fell in Thursday’s premarket session as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/snowflake-q3-2025-earnings-beat-estimates/cJITVQNRXi">traders looked past the quarterly beat</a> and expressed disappointment over the running quarter’s guidance.&nbsp;On the earnings&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fool.com/earnings/call-transcripts/2024/11/20/nvidia-nvda-q3-2025-earnings-call-transcript/">call,</a> Jensen Huang, President and CEO of the artificial intelligence (AI)&nbsp;chip maker, weighed in on the proposed tariff policy of the incoming administration under President-elect Donald Trump.During his campaign, Trump&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2024/02/04/trump-floats-more-than-60percent-tariffs-on-chinese-imports.html">threatened</a> to&nbsp;impose 60% or higher tariffs on Chinese goods if he were to be elected.The results of a Reuters poll of economists published on Wednesday showed that Trump would start off by imposing a blanket 40% tariff on goods imported from China. This is sharply higher than the 7.5%-25% rate he levied while he was in office between 2017 and 2020.The poll respondents, which includes economists from in and outside of mainland China, said a 60% tariff as early 2025 is unlikely as it would reignite inflationary pressure in the U.S., the report said.A radical measure such as this could trigger retaliation by China and precipitate into a trade war between the world largest and second-largest economies.Huang was asked about how the proposed tariffs would impact Nvidia’s China business.The executive said Nvidia would support the administration in whatever it decides. "And that’s our - the highest mandate," he said. "And then after that, do the best we can and just as we always do," he added.Outlining the three things the company would do simultaneously, Huang said it would comply with any regulation fully, support its customers to the best of its abilities and also compete in the marketplace.Nvidia is facing the brunt of the Joe Biden administration’s decision to ban the export of high-performance chips to China. To offset any potential negative impact from the move, the company developed export-compliant Hopper products.&nbsp;On the earnings call, CFO Colette Kress said China data center revenue increased sequentially in the third quarter due to the shipments of these export-compliant products. That said, China’s contribution to data center revenue remained well below the levels that prevailed ahead of the export controls, she added.The 10-Q report filed with the SEC showed that China, including Hong Kong, contributed $5.42 billion or 15.5% to Nvidia's total revenue of $35.08 billion. The region witnessed roughly 34% YoY growth.<figure class="image"><a href="https://stocktwits.com/symbol/NVDA"><img style="aspect-ratio:632/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nvda_sentiment_c652a41da2.png" alt="nvda-sentiment.png" width="632" height="137"></a><figcaption>NVDA sentiment and message volume November 21, 2024, premarket as of 7:57 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward Nvidia stock stayed ‘extremely bullish’ (80/100), with message&nbsp; volume ‘extremely high.’In Thursday’s premarket session, as of 7:57 am ET, the stock clawed back early losses and was down merely 0.86% at $144.64.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/snowflake-q3-2025-earnings-beat-estimates/cJITVQNRXi">Snowflake Stock Jumps Over 21% In Premarket Following Beat-and-Raise Q3: Retail Braces For ‘Parabolic’ Run</a>

China, including Hong Kong, contributed $5.42 billion or 15.5% to the total revenue of $35.08 billion.

Nvidia CEO Commits To Trump Policy Support, Reveals Strategy To Offset Tariff Challenges: Retail Stays Bullish

Trump eyes 60% or higher tariffs on Chinese goods but economists think a blanket 40% rate looks likely.

Equity

Trump eyes 60% or higher tariffs on Chinese goods but economists think a blanket 40% rate looks likely.


NVDU
Direxion Daily NVDA Bull 1.5X Shares

Feed

News

Sentiment

Fundamentals

Info

Latest NVDU News

NVDUDirexion Daily NVDA Bull 1.5X Shares